FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
Selank / Semax Blend 5/5mg research peptide vial
Cognitive

Selank / Semax Blend

Nootropic research blend

A combined nootropic research blend of selank and semax.

$99

In stock · ships in 1–2 business days

  • ✓ 99.61% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
blendnootropic research

Research Summary

This blend combines the tuftsin analog selank with the ACTH-derived peptide semax, studied together in preclinical neuro-research models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

Selank / Semax Blend: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is in the blend?

This research blend combines two synthetic heptapeptides in one lyophilized vial, 5mg of each:

  • Selank, Thr-Lys-Pro-Arg-Pro-Gly-Pro, a tuftsin analog [1].
  • Semax, Met-Glu-His-Phe-Pro-Gly-Pro, an ACTH(4-7) analog extended with Pro-Gly-Pro [2].

Each component has its own research page with a full literature summary, mechanisms, and references. This page covers only what is specific to the pair. Both peptides come from the same Moscow research program, and most of the literature on each comes from a small number of Russian institutes, much of it in Russian.

Selank / Semax Blend molecular identity
CompositionSelank 5mg and Semax 5mg per vial
Selank sequenceThr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
Selank formula / MWC33H57N11O9, 751.9 g/mol (PubChem CID 11765600)
Semax sequenceMet-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Semax formula / MWC37H51N9O10S, 813.9 g/mol (PubChem CID 9811102)

What the two peptides share

A common C-terminal tail

Both peptides end in Pro-Gly-Pro, a proline-rich tripeptide. Their N-terminal portions are unrelated: tuftsin for Selank, the ACTH(4-7) fragment for Semax [1] [2].

Overlapping enzyme findings

In a 2001 study of human serum, both Selank and Semax inhibited enkephalin-degrading enzymes, with reported IC50 values of about 20 and 10 micromolar respectively. Their pentapeptide fragments were also active, while tri-, tetra-, and hexapeptide fragments were not [3].

Shared origin and evidence base

Both peptides were studied by largely the same group of Moscow researchers, and several papers list the same senior authors on work about each compound [3] [8] [9]. That shared origin is useful context: the evidence for each component is concentrated in a small research network, and independent replication of either is limited.

Overlapping research themes

Each peptide has been studied individually for effects on brain-derived neurotrophic factor in rodents [4] [5]. Their best-studied mechanisms otherwise differ: GABA-A receptor modulation and immune gene expression for Selank [6], and neurotrophin transcription and monoamine effects for Semax [7].

Research on the combination

We found no published study that tested Selank and Semax together as a combined preparation. Studies that include both peptides have compared them side by side as separate treatments:

  • In rats with 6-OHDA lesions of dopaminergic neurons, neither peptide changed motor activity, while Selank, but not Semax, reduced anxiety-related behavior in the elevated plus maze [8].
  • A 2020 resting-state fMRI study in 52 healthy volunteers gave participants either Selank, Semax, or placebo, and reported both shared and peptide-specific changes in functional connectivity between the right amygdala and the right temporal cortex [9].
  • The 2001 serum enzyme study tested each peptide separately [3].

Because the pair has not been studied as a combination, there is no evidence that the two interact, add to each other, or behave differently together than apart. Any such question would need to be tested directly. FDA's 2026 briefing document on Semax noted that Semax is marketed online both alone and in combination with Selank [10]; that observation describes the market, not any research finding.

Regulatory status

  • Not FDA approved. Neither Selank, Semax, nor any combination of them is approved by the U.S. Food and Drug Administration.
  • Semax. At FDA's Pharmacy Compounding Advisory Committee meeting on July 23 and 24, 2026, the committee voted 8 to 5 to recommend Semax for the 503A bulks list, against the FDA staff recommendation [10] [11]. The vote is non-binding.
  • Selank. Selank was not reviewed at that meeting. FDA's safety-risks page (content current as of April 22, 2026) lists both Selank acetate and Semax among nominated substances that were later withdrawn, noting possible immunogenicity risks and insufficient human safety information [12].
  • Status checked 2026-10-12. See the individual Selank and Semax pages for detail.

Rejuvatide supplies this blend strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

Every Rejuvatide lot of the Selank / Semax Blend is tested as a finished blend by an independent laboratory for purity by HPLC and identity by mass spectrometry, and is also tested for endotoxin. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

Browse all neuroscience research compounds, or see our FAQ for ordering and shipping questions.

Storage of lyophilized material

The blend ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of Selank / Semax Blend.

99.61%HPLC purity
Lot 60730-40Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

Selank / Semax Blend FAQ

What is in the Selank / Semax Blend?

Each vial contains 5mg of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and 5mg of Semax (Met-Glu-His-Phe-Pro-Gly-Pro) as a lyophilized powder.

Has the Selank and Semax combination been studied?

Not as a combination. Published studies that include both peptides tested them separately, side by side. There is no evidence about how the two behave together.

Is the blend FDA approved?

No. Neither peptide, nor any combination of them, is FDA approved. An FDA advisory committee voted in July 2026 to recommend Semax for the 503A compounding list, which is non-binding; Selank was not reviewed.

How is the blend tested?

Each lot is tested as a finished blend by an independent laboratory for HPLC purity, mass-spec identity, and endotoxin. The certificates are published on the product page and in the COA library, matched to the lot number on the vial.

Is the blend for human use?

No. Rejuvatide sells this blend for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. Selank, Compound CID 11765600. National Library of Medicine. Source
  2. PubChem. Semax (ACTH (4-7), Pro-Gly-Pro-), Compound CID 9811102. National Library of Medicine. Source
  3. Kost NV, Sokolov OIu, Gabaeva MV, et al. Bioorg Khim. 2001;27(3):180-3. PubMed 11443939
  4. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Brain Res. 2006;1117(1):54-60. PubMed 16996037
  5. Kolik LG, Nadorova AV, Antipova TA, et al. Bull Exp Biol Med. 2019;167(5):641-644. PubMed 31625062
  6. Vyunova TV, Andreeva L, Shevchenko K, et al. Protein Pept Lett. 2018;25(10):914-923. PubMed 30255741
  7. Eremin KO, Kudrin VS, Saransaari P, et al. Neurochem Res. 2005;30(12):1493-500. PubMed 16362768
  8. Slominsky PA, Shadrina MI, Kolomin TA, et al. Dokl Biol Sci. 2017;474(1):106-109. PubMed 28702721
  9. Panikratova YR, Lebedeva IS, Sokolov OY, et al. Dokl Biol Sci. 2020;490(1):9-11. PubMed 32342318
  10. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Semax-related bulk drug substances (Semax (free base) and Semax acetate). Source
  11. Regulatory Affairs Professionals Society. FDA advisory committee backs two more peptides, rejects one for compounding list (July 24, 2026). Source
  12. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source